Cilostazol: Treatment of intermittent claudication

Annals of Pharmacotherapy

Volumn 35, Issue 1, 2001, Pages 48-56

  Reilly, Muredach P ^a   Mohler, Emile R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antiplatelet; Cilostazol; Intermittent claudication; Peripheral arterial disease; Restenosis; Vasodilator

Indexed keywords

CILOSTAZOL; CYCLIC AMP PHOSPHODIESTERASE; PENTOXIFYLLINE;

AREA UNDER THE CURVE; ARTERY DISEASE; CLINICAL TRIAL; DIARRHEA; HEADACHE; HEART PALPITATION; HUMAN; INTERMITTENT CLAUDICATION; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RESTENOSIS; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; VASODILATATION;

CLINICAL TRIALS; HUMANS; INTERMITTENT CLAUDICATION; PHOSPHODIESTERASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; TETRAZOLES; VASODILATOR AGENTS;

EID: 0035107020     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19408     Document Type: Review

References (60)

1. The epidemiology of peripheral arterial disease: Importance of identifying the population at risk
2. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline or nafronyl
3. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease
4. A comparison of cilostazol and pentoxifylline for intermittent claudication
5. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial
6. Cilostazol or pentoxifylline for claudication?
7. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor sepharose chromatography
8. Cilostazol
9. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells
10. Comparison of cilostazol versus ticlopidine therapy after stent implantation
11. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty
12. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors
13. Cyclic nucleotides and phosphodiesterases in platelets
14. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury
15. Clinical effects of oral cilostazol on suppression of platelet function in patients with cerebrovascular disease
16. Comparison of the inhibitory effects of cilostazol, acetyl-salicylic acid and ticlopidine on platelet functions ex vivo: Randomized double blind crossover study
17. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells
18. Comparative study of anti-platelet drugs in vitro: Distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses
19. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo
20. Functional relationship between cyclic AMP-dependent protein phosphorylation and platelet inhibition
21. Shear-induced platelet-aggregation in normal subjects and stroke patients
22. Effect of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle
23. Effects of selective phosphodiesterase inhibitors on isolated coronary lung and renal arteries from man and rat
24. Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator
25. Change in anti-platelet and vasodilating effects after chronic administration of cilostazol and beraprost
26. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture
27. Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppress mitogenesis of rat mesangial cells
28. Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells
29. The effect cilostazol, a cyclic nucleotide phosphodiesterase III inhibitor, on heparin-binding EGF-like growth factor expression in macrophages and vascular smooth muscle cells
30. Change of cyclic-AMP and cyclic-AMP phosphodiesterase in the progression and regression of experimental atherosclerosis
31. Effects of single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery
32. Effect of the novel antiplatelet agent, cilostazol, on plasma lipoproteins in patients with intermittent claudication
33. Involvement of the rapid increase in cAMP content in the vandate-stimulated release of lipoprotein lipase activity from rat fat pads
34. Regulation of VLDL secretion in primary culture of rat hepatocytes: Involvement of cAMP and cAMP-dependent protein kinases
35. Phase I study of cilostazol. Safety evaluation at increasing single doses in healthy volunteers
36. The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man
37. Pharmacokinetics of multiple-dose oral cilostazol in middle-age and elderly men and women
38. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics
39. The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man
40. Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites
41. A randomized comparison of anti-platelet and anticoagulant therapy after placement of coronary-artery stent
42. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients
43. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting
44. Thrombotic thrombocytopenic purpura associated with clopidogrel
45. Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen
46. Antiplatelet treatment with cilostazol after stent implantation
47. Impact of cilostazol on neointimal proliferation following Palmaz-Schatz stent implantation: A prospective randomized trial
48. Impact of cilostazol on intimal proliferation after directional coronary atherectomy
49. Effects of probucol and cilostazol alone and in combination on the frequency of poststenting restenosis
50. Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation
51. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty
52. Randomized trial of coronary intervention with antibody against platelet GP IIβ/IIIα integrin for reduction of clinical restenosis: Results at six months
53. Effect of oral milrinone on mortality in severe chronic heart failure
54. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure
55. Effect of CYP3A inhibition on the metabolism of cilostazol
56. Effect of omeprazole on the metabolism of cilostazol
57. Update: Clinically significant cytochrome P-450 drug interactions